• ORAI2 and Early Postirradiation Salivary Fibrosis

  2026-09-13

  The reference study identifies ORAI2-dependent store-operated calcium entry as an early driver of postirradiation salivary gland fibrosis and defines an ORAI2/JNK/NFAT1/TGF-β1 signaling axis. Its combined cell, mouse, transcriptomic, and pharmacological design supports calcium signaling as a mechanistic target while also highlighting the need for pathway-level rather than ORAI2-specific interpretation of SOCE inhibitors.

• SB 431542 for Reliable Cell Assays

  2026-09-12

  A scenario-based guide to using SB 431542 (SKU A8249) as a selective ALK5 inhibitor in proliferation, viability, and immunology workflows. It connects mechanism, assay controls, formulation, storage, interpretation, and vendor selection to practical laboratory decisions.

• C34 TLR4 Inhibitor: Evidence and Workflow

  2026-09-11

  C34 is a selective small molecule TLR4 inhibitor for inflammatory signaling research. Product information reports functional inhibition near 10 μM in vitro and activity near 1 mg/kg in endotoxemia and necrotizing enterocolitis models, while peer-reviewed work uses C34 as a TLR4 reference inhibitor in microglial assays.

• NETs and IL-36R Feedback in Psoriasis

  2026-09-11

  The reference study defines a mechanistic link between TLR3/P2X7R-driven NETosis and IL-36R-dependent inflammatory amplification in psoriasiform disease. Its combined neutrophil, keratinocyte, receptor-deficiency, and imiquimod-model experiments suggest that interrupting NET formation or IL-36R signaling may reduce inflammatory feedback, while also highlighting important limits of translating acute mouse models to human psoriasis.

• Ginsenoside Rg1 in Neuroprotection Workflows

  2026-09-10

  Ginsenoside Rg1 provides a practical way to connect behavioral, synaptic, inflammatory, and gut-barrier measurements in anesthesia-related neuroprotection research. This workflow translates Treg-dependent gut–immune–brain findings into formulation controls, assay choices, and troubleshooting checkpoints.

• FITC-Concanavalin A (ConA) Conjugate Guide

  2026-09-10

  FITC-Concanavalin A (ConA) Conjugate is a fluorescent lectin conjugate for visualizing α-D-glucose and α-D-mannose moieties on glycoproteins and glycolipids in cell and tissue samples. It supports cell surface carbohydrate detection, immunofluorescence staining, and flow cytometry, but it should not be interpreted as a specific protein marker or used as a general non-carbohydrate probe.

• FGF-19 at the Renal–Metabolic Interface

  2026-09-09

  A translational framework for using Recombinant Human FGF-19 to investigate endocrine signaling, FGFR4 biology, and potential links to the WIP1–p38 MAPK–pyroptosis axis in septic acute kidney injury without overstating the current evidence.

• Anti-HMGB1 Rabbit Monoclonal Antibody Guide

  2026-09-09

  The Anti-HMGB1 Rabbit Monoclonal Antibody MA3057 supports research detection of HMGB1 in human, mouse, and rat samples by Western blot, immunohistochemistry, and flow cytometry. It is intended for research workflows only, with no diagnostic or therapeutic use and no directly matched paper evidence supplied for this specific SKU.

• Urolithin A: A Translational Mitochondrial Strategy

  2026-09-08

  Urolithin A offers a mechanistically distinct approach to mitochondrial quality control research. This thought-leadership article connects mitophagy, mitochondrial biogenesis, and inflammatory metabolism with the SIRT4–GDH–glutamine axis implicated in hepatic stellate cell activation, while defining practical boundaries for translational validation.

• Triamcinolone Protocol and QC Guide

  2026-09-08

  Triamcinolone is a synthetic glucocorticoid agonist for controlled in vitro studies of glucocorticoid receptor signaling, inflammation, and immunosuppression. This guide addresses dissolution, controls, storage, and assay quality; the compound is for scientific research only and should not be used in diagnostic, clinical, or therapeutic workflows.

• Human iPSC Hepatobiliary Organoids: Study Insights

  2026-09-07

  Wu et al. developed a staged, three-dimensional system that generates hepatobiliary organoids from human induced pluripotent stem cells without exogenous support cells or genetic manipulation. The resulting organoids reproduced several hepatocyte and cholangiocyte functions, providing a useful platform for studying liver development, drug metabolism, and regenerative medicine.

• GW 6471: Turning PPARα Antagonism into Insight

  2026-09-07

  PPARα biology sits at the intersection of lipid handling, hepatotoxicity, and metabolic disease. This thought-leadership article examines how GW 6471 can help translational researchers distinguish receptor-dependent effects from downstream association, using PFHxS-induced liver injury in zebrafish as a mechanistic anchor. It also outlines a disciplined workflow, clarifies what can and cannot be translated across models, and positions pharmacological antagonism as a strategic complement to transcriptomics, biochemical testing, and genetic perturbation.

• c-Myc Peptide for Immunoassay Workflows

  2026-09-05

  Use the c-Myc Peptide as a sequence-specific competition reagent to validate antibody binding, release tagged fusion proteins, and distinguish epitope-dependent signal from nonspecific capture. This workflow also provides a disciplined bridge to transcription-factor studies inspired by selective autophagy control of IRF3, without confusing an assay control with a biological mechanism.

• HHV-7 DNA in Ocular Toxoplasmosis

  2026-09-04

  Miyase et al. detected human herpesvirus 7 and Toxoplasma gondii DNA together in vitreous humor from a patient with recurrent, treatment-refractory ocular toxoplasmosis. The case highlights multiplex PCR during vitrectomy as a clinically informative diagnostic strategy while suggesting, but not proving, that HHV-7 reactivation may contribute to persistent infectious uveitis.

• HRP Goat Anti-Mouse IgG (H+L) Antibody

  2026-09-04

  This reagent provides an HRP-based detection step for mouse-derived primary antibodies in Western blotting, ELISA, IHC, and ICC. It should not be used as a default secondary for non-mouse primary antibodies, and assay-specific titration is required because the dossier does not provide a universal working dilution or incubation condition.

8381 records 4/559 page Previous Next 12345 下5页 Last page